{"id":"W2335344368","doi":"10.1097/ogx.0b013e3182877729","title":"Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Obstetrical & Gynecological Survey","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Docetaxel; Medicine; Capecitabine; Gemcitabine; Bevacizumab; Breast cancer; Oncology; Cyclophosphamide; Chemotherapy; Internal medicine; Doxorubicin; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001915548,0.0002842026,0.000674411,0.0001169575,0.0001119967,0.00003723932,0.0001802618,0.000261105,0.0213807],"category_scores_gemma":[0.0009557356,0.0001924983,0.0002139526,0.0007139211,0.00007233847,0.00006205947,0.00006447325,0.0002185912,0.0005612674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004852062,"about_ca_system_score_gemma":0.0001228407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001001854,"about_ca_topic_score_gemma":0.0001635771,"domain_scores_codex":[0.9980022,0.0001478404,0.0003710536,0.0005553521,0.0002433173,0.0006802392],"domain_scores_gemma":[0.9957146,0.002970593,0.00007468302,0.0002344862,0.0003662216,0.0006393876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002303759,0.002532395,0.2723567,0.00004501508,0.0003708448,0.00004031861,0.00009309287,0.00001488623,0.005923311,0.00006812189,0.1586323,0.5576193],"study_design_scores_gemma":[0.005853456,0.001738377,0.957203,0.000009925761,0.00007176849,0.00001450279,0.0000128629,0.0001445908,0.0004566044,0.00008875625,0.0341606,0.0002455853],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9767039,0.001021307,0.0002041517,0.015603,0.001103766,0.003538491,0.0005456001,0.000185347,0.001094386],"genre_scores_gemma":[0.9830908,0.0001624038,0.00100908,0.009285019,0.0002927199,0.001410439,0.0001113277,0.00003516365,0.004603064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6848463,"threshold_uncertainty_score":0.9795139,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04641934878625111,"score_gpt":0.3535923177234178,"score_spread":0.3071729689371667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}